Αρχική World News FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma World News FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma Από Ogkologos - 1 Απριλίου, 2026 285 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CA209-8UT (SWOG 1826) Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Extension of Indications for Venetoclax 14 Μαΐου, 2021 Combination Chemo Helps People with Leiomyosarcoma Live Longer 2 Οκτωβρίου, 2024 Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... 6 Δεκεμβρίου, 2021 FDA Approves Crizotinib for Children and Young Adults with Relapsed or... 19 Ιανουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... Breast Cancer Survivor Thanks Early Detection For Saving Her Life ASCO Annual Meeting 2023: Improving Patients’ Lives Through Collaboration, Research, and... Can a Biopsy Make My Cancer Spread?